Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02154529 · ClinicalTrials.gov registry record · Phase 1
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1 study, sponsored by Kadmon Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT02154529 is a Phase 1 study that was terminated before completion, run by Kadmon Corporation. The registered enrollment target is 17 participants.
The verdict
NCT02154529, a Phase 1 study, was terminated before completion, sponsored by Kadmon Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
Evaluate the safety and tolerability and determine the maximum tolerated dose (MTD) of the combination of tesevatinib and trastuzumab in subjects with HER2-positive metastatic breast cancer
Interventions
- DRUG Trastuzumab
- DRUG Tesevatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-09-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02154529
The ClinicalTrials.gov registry entry for NCT02154529 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kadmon Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trastuzumab is the first listed.
NCT02154529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02154529 about?
NCT02154529 is a clinical study titled "Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer". Evaluate the safety and tolerability and determine the maximum tolerated dose (MTD) of the combination of tesevatinib and trastuzumab in subjects with HER2-positive metastatic breast cancer
What is the current status of trial NCT02154529?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2014-05. Estimated completion is 2015-09-13.
What interventions are being tested in trial NCT02154529?
The interventions under investigation include: Trastuzumab (DRUG), Tesevatinib (DRUG).
Who is sponsoring clinical trial NCT02154529?
This trial is sponsored by Kadmon Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.